Literature DB >> 29123862

Management of maternal anaphylaxis in pregnancy: a case report.

Yasunobu Tsuzuki1, Mitsuo Narita2, Masayuki Nawa3, Urara Nakagawa4, Toshiaki Wakai4.   

Abstract

Case: A 26-year-old woman (gravida 2, para 1) at 25 weeks' gestation was brought to the emergency department because of anaphylactic symptoms. She reported eating Japanese soba and developed symptoms of dyspnea, generalized itchy rash, abdominal pain, and severe uterine contractions within 15-30 min of eating. She was immediately treated by normal saline infusion, two injections of epinephrine (intramuscularly), and a nebulized short-acting β2-receptor agonist, followed by H1-antihistamine and methylprednisolone. Obstetrical management was undertaken by an obstetrician. Outcome: The patient recovered rapidly without a biphasic reaction of anaphylaxis. After 11 weeks, a healthy, neurologically intact baby was born.
Conclusion: Management of anaphylaxis in pregnant patients is basically the same of that in non-pregnant ones. Treatment should commence immediately to prevent further development of the anaphylaxis reaction and fetal neurological deficiency.

Entities:  

Keywords:  Anaphylactic shock; fetal brain damage; fetal distress; food allergy

Year:  2016        PMID: 29123862      PMCID: PMC5667276          DOI: 10.1002/ams2.238

Source DB:  PubMed          Journal:  Acute Med Surg        ISSN: 2052-8817


Introduction

Anaphylaxis is a rare event during pregnancy, but its onset may trigger maternal hypotension leading to intrapartum asphyxia and, eventually, the risk of severe fetal brain damage. Furthermore, the risk of cesarean delivery in anaphylactic patients in pregnancy is high (74%).1 We report a case of maternal anaphylaxis that was caused by food allergy and discuss the management of anaphylaxis in a pregnant patient.

Case

A 26‐year‐old woman (gravida 2, para 1) at 25 weeks’ gestation was brought to the emergency department because of severe uterine contractions, dyspnea, generalized itchy rash, abdominal pain, and peripheral cyanosis. She reported eating buckwheat noodles (soba) and tempura (fish, shrimp, crab, and vegetables) and developed the symptoms within 15–30 min of eating. She had a medical history of atopic dermatitis, but no history of food allergies or anaphylaxis. She was lucid. On examination, her blood pressure was 104/72 mmHg, heart rate was 112 b.p.m., respiratory rate was 40 breaths/min, oxygen saturation was 100% (with high‐flow humidified supplemental 100% oxygen 6 L/min by mask), and body weight was 43 kg. The patient was diagnosed with anaphylaxis because of a suspected food allergy, and she was immediately treated with normal saline infusion, an i.m. injection of 0.4 mg epinephrine, and a nebulized short‐acting β2‐receptor agonist. We manually displaced her uterus to the left to prevent inferior vena cava compression. The treatment was effective, but her generalized itchy rash and abdominal pain persisted. She received an additional 0.4 mg epinephrine i.m. as well as an H1‐antihistamine and methylprednisolone. Serum allergen‐specific immunoglobulin E (IgE) testing (total IgE 360 IU/mL, dust mite 86 UA/mL, buckwheat 0.1 UA/mL, wheat 1.79 UA/mL) was carried out in the emergency department; total serum tryptase was increased on day 1 (15.5 μg/mL) but decreased by day 2 (3.9 μg/mL). Obstetrical management was undertaken by an obstetrician for threatened preterm labor, but the fetal heart rate was almost normal (140–160 beats/min) with variability (Fig. 1), and ultrasonography showed a vital fetus with no fetal distress. A cesarean delivery was not undertaken. After the second injection of epinephrine, the patient's condition stabilized and both the mother and fetus rapidly recovered. A biphasic reaction of anaphylaxis did not occur. However, the patient required fetal monitoring and maternal treatment of threatened preterm labor for several days. After the seventh hospital day, the patient was discharged. Eleven weeks later, the baby was born without neurological deficiency.
Figure 1

Fetal heart rate during maternal anaphylaxis. The mother experienced strong and frequent uterine contractions (lower panel), but examination of the fetus revealed a normal heart rate (140–160 b.p.m) with variability (upper panel).

Fetal heart rate during maternal anaphylaxis. The mother experienced strong and frequent uterine contractions (lower panel), but examination of the fetus revealed a normal heart rate (140–160 b.p.m) with variability (upper panel). The cause of the allergy was investigated after birth, because skin prick and challenge test are contraindicated in pregnancy considering the risk of inducing anaphylaxis. The skin prick test was positive for dust mite (4.4 mm × 1.1 mm), buckwheat (3.7 mm × 4.2 mm), and wheat (4.7 mm × 3 mm) and was negative for shrimp (0 mm). An oral food challenge for wheat and buckwheat revealed the anaphylaxis was caused by a buckwheat allergy. She eliminated buckwheat from her diet and has experienced no further allergy symptoms.

Discussion

Anaphylaxis is defined as a serious, generalized or systemic, allergic or hypersensitivity reaction that can be life‐threatening or fatal.2 Anaphylaxis is a relatively infrequent event during pregnancy.2, 3, 4, 5 Management of anaphylaxis in pregnant patients is basically the same as that in non‐pregnant ones.3, 4, 5, 6 Symptoms of anaphylaxis include respiratory (e.g., wheeze, dyspnea), gastrointestinal (e.g., vomiting, abdominal pain), skin and mucosal (e.g., urticaria, itchy rash, swelling of lips), and cardiovascular and central nervous systems (e.g., reduced blood pressure, feeling faint, headache).7 Potential pregnancy‐related symptoms and signs of anaphylaxis are lower back pain, fetal distress, uterine cramps, preterm labor, and vulvar or vaginal itching.3 Anaphylaxis may also trigger maternal hypotension and hypoxemia. Maternal hypoxemia and hypotension are potentially life‐threatening to both mother and fetus. Maternal hypoxemia can lead to intrapartum asphyxia, and maternal hypotension and vasoconstriction can result in decreased uterine blood flow.3, 4, 5, 6 Risks to the fetus include hypoxic–ischemic encephalopathy, severe central nervous system damage, or death.3, 4, 5, 6 Initial treatment includes improving maternal airway, breathing, and circulation, removing causative agents, and injecting 0.01 mg/kg epinephrine in the mid‐outer thigh.3 The initial dosing is based on recommendations of several allergy organizations, particularly, epinephrine (0.01 mg/kg of a 1:1000, 1 mg/mL solution) i.m. injection to a maximum of 0.5 mg in adults and 0.3 mg in children.2, 7, 8 It is important to re‐evaluate the allergic symptoms of the patient, to prevent permanent damage to the fetus. If allergy symptoms recur or do not improve, epinephrine injection can be needed repeatedly every 5–15 min.2, 3, 7 Therefore, our patient was immediately treated with normal saline infusion, supplemental 100% oxygen, and two i.m. injections of epinephrine. Patients may require cesarean delivery to avoid fetal hypoxemia and prevent severe fetus damage. In cases of anaphylaxis during pregnancy, both mother and fetus must be treated. Therefore, the patient must be seen by a specialist team comprising obstetrics, neonatology, and anesthesiology for medical and surgical obstetric management, such as fetal monitoring, maternal treatment of threatened preterm labor, and preparing cesarean delivery.3 The epinephrine auto‐injector should be prepared for pregnant women who has potential risk of anaphylaxis.

Conclusion

We present a case of maternal anaphylaxis caused by food allergy, with details of patient management. Allergic and obstetric management should be commenced immediately to prevent further development of the anaphylactic reaction and fetal brain damage. Drugs for anaphylaxis, such as epinephrine, antihistamines, glucocorticoids, and vasopressors, can be used safely without major side‐effects in pregnancy. Certainly, potential side‐effects of any drugs should be considered.

Conflict of interest

None declared.
  8 in total

1.  Maternal anaphylaxis and fetal brain damage after intrapartum chemoprophylaxis.

Authors:  Alberto Berardi; Katia Rossi; Francesca Cavalleri; Angela Simoni; Lorenzo Aguzzoli; Giuseppe Masellis; Fabrizio Ferrari
Journal:  J Perinat Med       Date:  2004       Impact factor: 1.901

Review 2.  Anaphylactic shock in pregnancy: a case study and review of the literature.

Authors:  K Chaudhuri; J Gonzales; C A Jesurun; M T Ambat; S Mandal-Chaudhuri
Journal:  Int J Obstet Anesth       Date:  2008-10       Impact factor: 2.603

3.  Anaphylaxis in pregnancy: a rare cause of neonatal mortality.

Authors:  Alberto Berenguer; Alexandra Couto; Vera Brites; Rosário Fernandes
Journal:  BMJ Case Rep       Date:  2013-01-11

4.  Anaphylaxis in the obstetric patient: analysis of a statewide hospital discharge database.

Authors:  Zuber D Mulla; Marianne S Ebrahim; José L Gonzalez
Journal:  Ann Allergy Asthma Immunol       Date:  2010-01       Impact factor: 6.347

Review 5.  Anaphylaxis during pregnancy.

Authors:  F Estelle R Simons; Michael Schatz
Journal:  J Allergy Clin Immunol       Date:  2012-08-04       Impact factor: 10.793

Review 6.  Anaphylaxis.

Authors:  F Estelle R Simons
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

7.  World Allergy Organization anaphylaxis guidelines: summary.

Authors:  F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

8.  International consensus on (ICON) anaphylaxis.

Authors:  F Estelle R Simons; Ledit Rf Ardusso; M Beatrice Bilò; Victoria Cardona; Motohiro Ebisawa; Yehia M El-Gamal; Phil Lieberman; Richard F Lockey; Antonella Muraro; Graham Roberts; Mario Sanchez-Borges; Aziz Sheikh; Lynette P Shek; Dana V Wallace; Margitta Worm
Journal:  World Allergy Organ J       Date:  2014-05-30       Impact factor: 4.084

  8 in total
  1 in total

Review 1.  Mastocytosis: Fertility and Pregnancy Management in a Rare Disease.

Authors:  Jacqueline Ferrari; Pietro Benvenuti; Elisa Bono; Nicolas Fiorelli; Chiara Elena
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.